This Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) provides $390,635 to the University of Pittsburgh to develop and evaluate a novel intervention targeting prenatal depressive symptoms to encourage tobacco and cannabis cessation among marginalized pregnant individuals.
The key products and services to be delivered under this award include: 1) Conducting formative research on the experiences of pregnant and postpartum individuals from minoritized groups who use both tobacco and cannabis, to understand the role of depressive symptoms in prenatal dual use; 2) Co-creating a new intervention with a community collaborative to address prenatal depressive symptoms and promote tobacco and cannabis cessation; and 3) Conducting a single-group feasibility trial of the new intervention to assess its acceptability and feasibility, in preparation for future efficacy evaluation. This research aims to amplify the voices of underrepresented populations disproportionately affected by prenatal tobacco and cannabis co-use, and develop an intervention tailored to their unique needs.
Generated 2/25/25, 5:25 AM